Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
[allergic bronchopulmonary aspergillosis]
Allergic
bronchopulmonary
aspergillosis
(
ABPA
)
is
a
severe
complication
in
patients
with
cystic
fibrosis
(
CF
)
,
resulting
in
deterioration
of
lung
function
and
impairment
of
overall
prognosis
.
Standard
therapy
consists
of
high
dosage
,
long
-term
corticosteroid
treatment
.
This
carries
the
risk
of
serious
side
effects
such
as
immune
suppression
,
diabetes
and
osteoporosis
.
Antifungal
drugs
such
as
itraconazole
may
cause
interactions
with
other
drugs
and
drug
levels
need
to
be
monitored
.
Omalizumab
treatment
has
been
tried
in
several
case
studies
.
This
was
a
retrospective
study
of
six
patients
(
four
female
,
two
male
,
age
4
-
33
years
old
)
with
CF
and
ABPA
treated
with
omalizumab
within
an
observation
period
of
7
.
5
years
.
All
patients
showed
clinical
and
laboratory
stability
or
even
an
improvement
within
the
treatment
and
post-treatment
observation
period
,
although
omalizumab
therapy
was
less
effective
in
patients
with
progressed
lung
disease
and
long
-term
ABPA
.
Side
effects
of
systemic
steroids
were
reduced
.
Omalizumab
has
the
potential
to
be
an
additional
and
solitary
treatment
option
in
patients
with
CF
and
ABPA
.
Early
onset
treatment
may
be
beneficial
and
patients
with
early
stage
of
lung
disease
seem
to
benefit
more
.
Diseases
Validation
Diseases presenting
"lung function"
symptom
allergic bronchopulmonary aspergillosis
congenital diaphragmatic hernia
lymphangioleiomyomatosis
monosomy 21
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom
